NASDAQ$SPRY
ARS Pharmaceuticals Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
ARS Pharmaceuticals reported financial results for the second quarter of 2024.
ARS Pharmaceuticals reported a net loss of $12.5 million for the second quarter of 2024. The company's cash, cash equivalents, and short-term investments were $218.7 million as of June 30, 2024, expected to fund operations for at least three years. The New Drug Application (NDA) for neffy is under review by the FDA, with a PDUFA date in early October 2024.
- neffy NDA under review by FDA with ongoing discussions to finalize labeling; PDUFA date in early October 2024.
- EURneffy recommended for approval by EMA’s CHMP; formal marketing authorization anticipated in Q3 2024.
- Outpatient study of neffy for urticaria on track to initiate in Q4 2024.
- $218.7 million in cash, cash equivalents and short-term investments as of June 30, 2024, providing an expected operating runway of at least three years.
Headline financials
Revenue & EPS history
ARS Pharmaceuticals · Revenue · Quarterly
$500K
Revenue by segment
ARS Pharmaceuticals · $22.7M total across 3 segments · Q1 2026
- Product revenue, net$17.5M—76.9%
- Revenue under supply agreements$2.74M—12.1%
- Revenue under collaboration agreements$2.49M—11.0%
Forward guidance
ARS Pharma is awaiting regulatory decisions on neffy and planning for its potential launch, while also expanding clinical studies and seeking partnerships for European commercialization.
Tailwinds
- Anticipated regulatory review decisions on the neffy NDA and European marketing authorization application.
- Projected cash runway and belief that it is well capitalized and prepared to support the successful launch of neffy in the U.S., if approved
- Planned studies of neffy for urticaria and timing thereof
- Potential benefits to urticaria patients if neffy is approved in this indication
- Belief that ARS Pharma will be able to enter into a partnership with a pharmaceutical partner with an established footprint in Europe for the commercialization of neffy in Europe
Headwinds
- Ability to obtain and maintain regulatory approval for neffy in any indication
- Possibility of new issues being identified that could delay or prevent the approval of neffy
- PDUFA target action date may be further delayed due to various factors outside ARS Pharma’s control
- Positive opinion from CHMP does not guarantee the EC will approve the related marketing authorization
- Potential safety and other complications from neffy
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-1.2%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+2.4%
Avg return
30 days after
41%
9 / 22 earnings
Positive
+22.8%
Q4 2024
Best reaction
-15.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.2% | -1.5% | +23.1% | |
| Q4 2025 | -0.1% | -7.4% | -9.6% | |
| Q3 2025 | +0.8% | -7.2% | +18.0% | |
| Q2 2025 | -5.2% | -15.8% | -39.8% | |
| Q1 2025 | -9.4% | +6.8% | +15.3% | |
| Q4 2024 | +22.8% | +12.9% | +27.7% | |
| Q3 2024 | -15.1% | -17.0% | -28.4% | |
| Q2 2024 | +2.7% | +16.7% | +26.1% | |
| Q1 2024 | -3.5% | -0.9% | -2.8% | |
| Q4 2023 | -0.6% | +14.9% | -2.6% | |
| Q3 2023 | +4.2% | +18.2% | +48.6% | |
| Q2 2023 | -0.9% | +2.2% | +7.0% | |
| Q1 2023 | +1.6% | +6.6% | -23.6% | |
| Q4 2022 | -5.0% | -17.0% | -18.1% | |
| Q3 2022 | -1.5% | -5.5% | +13.5% | |
| Q2 2022 | +1.0% | +7.2% | +3.2% | |
| Q4 2021 | -8.8% | +11.7% | +44.1% | |
| Q1 2022 | -8.8% | -4.5% | -11.6% | |
| Q3 2021 | +0.2% | +3.5% | -17.1% | |
| Q2 2021 | +2.6% | -1.0% | -4.0% | |
| Q1 2021 | +9.1% | +3.2% | -21.0% | |
| Q4 2020 | -5.9% | -9.6% | +4.5% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro